FCM
Farallon Capital Management’s Fate Therapeutics FATE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-31,900
| Closed | -$1.24M | – | 319 |
|
|
2022
Q1 | $1.24M | Sell |
31,900
-725,525
| -96% | -$28.1M | 0.01% | 214 |
|
|
2021
Q4 | $44.3M | Sell |
757,425
-1,553,973
| -67% | -$90.9M | 0.22% | 69 |
|
|
2021
Q3 | $137M | Buy |
2,311,398
+406,398
| +21% | +$24.1M | 0.64% | 42 |
|
|
2021
Q2 | $165M | Buy |
1,905,000
+5,000
| +0.3% | +$434K | 0.68% | 37 |
|
|
2021
Q1 | $157M | Sell |
1,900,000
-1,100,000
| -37% | -$90.7M | 0.78% | 36 |
|
|
2020
Q4 | $273M | Sell |
3,000,000
-125,000
| -4% | -$11.4M | 1.64% | 25 |
|
|
2020
Q3 | $125M | Sell |
3,125,000
-375,000
| -11% | -$15M | 0.86% | 40 |
|
|
2020
Q2 | $120M | Buy |
3,500,000
+500,000
| +17% | +$17.2M | 0.96% | 36 |
|
|
2020
Q1 | $66.6M | Buy |
3,000,000
+750,000
| +33% | +$16.7M | 0.57% | 34 |
|
|
2019
Q4 | $44M | Hold |
2,250,000
| – | – | 0.3% | 57 |
|
|
2019
Q3 | $34.9M | Sell |
2,250,000
-250,000
| -10% | -$3.88M | 0.26% | 56 |
|
|
2019
Q2 | $50.8M | Hold |
2,500,000
| – | – | 0.33% | 55 |
|
|
2019
Q1 | $43.9M | Buy |
2,500,000
+300,000
| +14% | +$5.27M | 0.33% | 54 |
|
|
2018
Q4 | $28.2M | Buy |
2,200,000
+1,670,000
| +315% | +$21.4M | 0.21% | 58 |
|
|
2018
Q3 | $8.63M | Buy |
+530,000
| New | +$8.63M | 0.05% | 85 |
|
|
2014
Q4 | – | Sell |
-171,196
| Closed | -$880K | – | 87 |
|
|
2014
Q3 | $880K | Sell |
171,196
-76,906
| -31% | -$395K | 0.01% | 78 |
|
|
2014
Q2 | $1.57M | Sell |
248,102
-26,898
| -10% | -$170K | 0.02% | 85 |
|
|
2014
Q1 | $2.68M | Sell |
275,000
-269,243
| -49% | -$2.62M | 0.05% | 68 |
|
|
2013
Q4 | $3.42M | Buy |
+544,243
| New | +$3.42M | 0.07% | 68 |
|